Supreme Court Rejects SEC's Ability to Seek Civil Penalties More than Five Years after an Alleged Fraud
Client Alert | 1 min read | 03.01.13
Earlier this week, the U.S. Supreme Court unanimously rejected the Securities and Exchange Commission's argument that the five-year statute of limitations period in 28 U.S.C. § 2462—the default limitations provision that governs civil penalties—begins to run when the fraud is discovered, not when the underlying violation occurred. Gabelli v. Securities and Exchange Commission (Feb. 27, 2013). The Court held that the discovery rule, which tolls the statute of limitations when a defendant's fraud prevents the plaintiff from realizing the injury, does not apply to government enforcement actions for civil penalties.
In Gabelli, the SEC filed fraud charges against individual defendants based on allegations of market timing. Although the SEC alleged violations from 1999 through August 2002, it did not file its complaint until April 2008, well after the five-year statute of limitations had lapsed. In an opinion by Chief Justice Roberts, the Court soundly rejected the SEC's request to apply the discovery rule, holding that "the five-year clock begins to tick [] when a defendant's allegedly fraudulent conduct occurs." The Court stressed that the "SEC as enforcer is a far cry from the defrauded victim the discovery rule evolved to protect" and recognized that, as a practical matter, the limitations period should not depend on the speculative nature of when a government agency—"with hundreds of employees, dozens of offices, and several levels of leadership"—knows or should know of a violation.
The Court's Gabelli decision may serve as a wake-up call to the SEC to hone and accelerate its investigation and enforcement practices. It may also have the immediate effect of increasing the number of SEC Staff requests for tolling agreements. In addition, the Court's decision will likely cause certain SEC inquiries to end with no enforcement action at all, given their age and investigative pace. Notably, the Gabelli decision only addresses civil monetary penalties and does not affect the SEC's other enforcement tools, such as injunctions and other forms of equitable relief.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26

